y

Congo: Five Priorities for a Peacebuilding Strategy




y

Congo: A Comprehensive Strategy to Disarm the FDLR




y

Burundi: To Integrate the FNL Successfully




y

Libya/Chad: Beyond Political Influence




y

Violencia y elecciones en los Grandes Lagos

Burundi escapó de una guerra civil y años de terror. Hoy se supone que vive en democracia, pero eso está por verse. Ante las próximas elecciones de mayo, y con el panorama de violencia política que asuela el país, parece imposible que éstas se celebren pacíficamente y bajo el paraguas de la democracia.




y

Libia e Ciad: Gheddafi e Déby, oltre la politica di influenza

I rapporti tra Gheddafi e Déby sono caratterizzati da una certa superficialità, dovuta alle tensioni passate e ai sospetti che nutrono l’uno per l’altro.




y

Cameroun: Le pays aura-t-il son Dadis ?

En Guinée, la période trouble sous la domination de la junte ne sera bientôt plus qu’un mauvais souvenir – si tout va bien. Le capitaine Dadis Camara, qui a été acclamé lors de son arrivée à la tête de l’Etat suite à la mort du président Conté, a fait de 2009 une année que les Guinéens veulent oublier, son évènement le plus marquant ayant été le massacre de 160 personnes dans le stade national en septembre 2009.




y

After MONUC, Should MONUSCO Continue to Support Congolese Military Campaigns?

For more than a year and a half, UN peacekeepers have continuously supported military operations conducted by the Congolese armed forces (FARDC) against the Rwandan rebels of the Democratic Forces for the Liberation of Rwanda (FDLR) in North and South Kivu.




y

Camerún: conflicto y elecciones en 2011

Después de 28 años bajo el gobierno de Paul Biya, Camerún se encuentra en una situación de inestabilidad grave que no sólo podría echar a perder las próximas elecciones presidenciales en 2011, sino que también pone en riesgo su papel como principal pilar de estabilidad en África Central.




y

Chad: Beyond Superficial Stability

The approaching elections could be important steps toward reviving democracy in Chad, but only if President Idriss Déby opens political space for the opposition beforehand.




y

Oil in Chad: The Fragile State’s Easy Victory over International Institutions

In numerous countries, the exploitation of oil has generated debate about its economic, social and geopolitical consequences.




y

Congo Crimes Should Be on the Agenda of the UN Security Council

The UN's release of a long awaited report on crimes committed in the Democratic Republic of Congo between 1993-2003 is not only an opportunity to re-examine the historical record of mass violence in DRC -- the scale and nature of which was often overlooked in the wake of the genocide in neighboring Rwanda -- but is also a chance to correct the terms of the deceptive and fragile peace some leaders wish to proclaim in the resource-rich Great Lakes region of Africa.




y

Congo: No Stability in Kivu despite Rapprochement with Rwanda

The attempt by Congo and Rwanda to end the deadly conflict in eastern Congo by a secret presidential deal and military force is failing and must be changed fundamentally by the Kinshasa government and the international community.




y

DR Congo: Why is there still a Kivu problem?

Despite three agreements between the rebels and the government, peace is still elusive in eastern Democratic Republic of Congo. The Kivus need regional dialogue and a clear, fair repatriation plan, argues Thierry Vircoulon at the International Crisis Group.




y

Burundi: From Electoral Boycott to Political Impasse

Burundi risks reversing the decade of progress it has enjoyed since its civil war ended unless the government resumes political dialogue with the opposition.




y

The Libyan crisis as seen from N’Djamena

Of the three political upheavals that have hit the Maghreb since the beginning of 2011, the Libyan crisis seems to be the most dangerous. First of all for Libya, because the popular uprising has taken the form of an armed rebellion that has cut the country in two; second, for the West, now that NATO, under the cover of United Nations Resolution 1973 (2011) and in order to protect the civilian population, has entered the conflict on the side of the rebels, rashly gambling on a speedy war; and finally, for the region as a whole, because the conflict recently "overflowed" into Tunisia, and neighbouring countries are beginning to feel its humanitarian consequences.




y

DR Congo's Electoral Law for 2011: Choosing Continuity

On 15 June 2011 the Congolese Parliament adopted, after nearly three months of de-bate, the new electoral law. The Senate, or upper house, controlled by the opposition, and the National Assembly, or lower house, controlled by the ruling coalition, both voted for an electoral law which ultimately remains very similar to that governing the 2006 elections. Parliament took three months of debate to reject most of the amend-ments proposed by the ruling party (PPRD). In doing so it demonstrated that the ex-ecutive could not simply trump its interests.




y

Implementing Peace and Security Architecture (I): Central Africa

More than a decade after the Economic Community of Central African States (ECCAS) was requested by the African Union (AU) to give life to a new peace and security architecture, political and security cooperation on the continent is still in need of reinforcement.




y

The Lord’s Resistance Army: End Game?

Insufficient political will has thwarted regional efforts to stop the murderous Lord’s Resistance Army (LRA) but vigorous diplomacy led by the African Union (AU), an immediate military push and complementary civilian initiatives could end the misery of thousands.




y

Préparer le Cameroun à l'après-Biya pour une stabilité durable

Le président sortant vient d'entamer un sixième mandat au Cameroun. Aujourd'hui, le pays est résolument tourné vers l'avenir et pense à l'après-Biya.




y

Au Burundi, les symptômes de la rechute

Quel est le lien entre Houellebecq et le Burundi? Apparemment aucun, sauf que la possibilité d'une île de l'écrivain pourrait s'intituler "la possibilité d'une rébellion" à propos de ce pays de l'Afrique des Grands Lacs.




y

Black Gold in the Congo: Threat to Stability or Development Opportunity?

Renewed oil interest in the Democratic Republic of the Congo (DRC) could nurture communal resentments, exacerbate deep-rooted conflict dynamics and weaken national cohesion.




y

Eastern Congo: Why Stabilisation Failed

The Kivus region of eastern Congo again faces escalating violence, including by a rebel force acting as a proxy of neighbouring Rwanda. To stop the repetitive cycle of rebellion and avoid large-scale killing, donors and African mediators need to move from crisis management to conflict resolution with the right set of pressures on Kigali and Kinshasa.




y

Burundi: Bye-bye Arusha?

Since the 2010 boycotted elections, Burundi is steadily drifting away from what was initially regarded as a peacemaking model, and violence from both the ruling party and the opposition is threatening stability.




y

Central African Republic is descending into anarchy

Since the March 24 coup by the Seleka, a loose coalition of Muslim rebels, the Central African Republic has been in free fall. There are about 400,000 internally displaced people, 64,000 refugees, and burned villages, largely in the western part of the country. Banditry, the rise of self-defense militias and clashes between Christian and Muslim communities are now part of daily life for this mineral-rich country in the heart of Africa. The expanding insecurity makes the delivery of humanitarian assistance difficult, and the United Nations has even warned of the risk of genocide.




y

Imaginación para salvar República Centroafricana. Cómo actuar con rapidez y eficacia para evitar la somalización del país.

Los conflictos en los países pequeños suelen agravarse debido a la indiferencia internacional. Sin embargo, en el caso de la República Centroafricana (RCA), el problema es ligeramente distinto. Hay una importante presencia internacional en este Estado, pero los actores principales han decidido mantenerse al margen y esperar en vez de intervenir activamente en la crisis.




y

The Security Challenges of Pastoralism in Central Africa

Sensible, inclusive regulation of pastoralism that has mitigated tension in parts of the Sahel should be extended to the Democratic Republic of Congo (DRC) and the Central African Republic (CAR), where conflicts have worsened with the southward expansion of pastoralism.




y

The CAR Crisis: Thinking Beyond Traditional Peacekeeping

The crisis that has been occurring in CAR is certainly the most dramatic in its history: more than 600 000 Central Africans are internally displaced or sought refuge in neighbouring countries; according to the United Nations, 1.7 million live in a constant situation of food insecurity and 878 000 need immediate medical assistance; Muslim communities are fleeing Bangui and the western region, subsistence economy no longer exists and the de facto partition of the country, caused by the sectarian violence, is gradually becoming a reality.




y

Burundi: Godefroid Niyombaré avait mis en garde Nkurunziza

Alors qu’une tentative de coup d’Etat contre Pierre Nkurunziza, émanant de l’ex-chef d’état-major, Godefroid Niyombaré, est en cours au Burundi, Thierry Vircoulon chercheur à l'International Crisis Group, explique qui est le général putschiste et analyse, plus généralement, l'appareil sécuritaire du Burundi.




y

Chad: Between Ambition and Fragility

Ahead of Chad’s presidential election on 10 April popular discontent is rising amid a major economic crisis, growing intra-religious tensions and deadly Boko Haram attacks. The regime that portrays itself as spearheading the fight against regional jihadism could see all sorts of violent actors gain influence at home if it pursues exclusionary politics and denies its people a viable social contract.




y

Rethinking the Way We Hold Schools Accountable

Test-based accountability has not generated the significant gains in student achievement that proponents intended, Helen F. Ladd contends.




y

Testing and Accountability in the NCLB Era

David Figlio and Eduwonkette discuss if today's testing and accountability policies accurately depict student performance and the size of the achievement




y

Why Are We Using Standardized Tests?

What should be included in a measure of school quality? If not by standardized test scores, how should we measure student achievement? Julian Vasquez Heilig and I each have some thoughts.




y

Data: Student Achievement in the Era of Accountability - Education Week

The Education Week Research Center looks at student scores on the National Assessment of Educational Progress from 2003 to 2015, a period overlapping with the No Child Left Behind Act.




y

Approval Deferred on ACT for Accountability in Wyo., Wis.

The U.S. Education Department says the states need more evidence to use the popular admissions test to measure high school achievement.




y

In Some States, ESSA Goals for English-Learners Are 'Purely Symbolic,' Report Finds

More than four years after the passage of ESSA, English-language-learner education policies across the country remain "disjointed and inaccessible," a new report concludes.




y

Accountability and Assessment Systems

Helen Janc Malone introduces this week's blog theme, "accountability and assessment systems." She writes that at the heart of the current accountability debate is a fundamental question, What is the purpose of all the collected assessment data? Are they an end game or a starting point to educational




y

Throwback Thursday: Achievement, Assessment, and Accountability

If we continue to focus on student growth and improvement as learners, keep track of that progress, and watch its impact on standard test results, will we be able to know if what we are doing is helping students develop as learners and thinkers.






y

WITHDRAWN: Very strong synergy between modified RANTES and gp41 binding peptides leads to potent anti-HIV-1 activity [Article]

This article, published ahead of print on 28 July 2008, has been withdrawn by the authors. Although moderate synergy between P2-RANTES and C peptides can be observed with high statistical significance in cell fusion assays, this synergy was not able to be verified in HIV viral assays. The authors regret the overstatement of synergy and will revise the paper for publication at a later date.




y

Efficacy of early oral switch with beta-lactams for low-risk Staphylococcus aureus bacteremia. [Clinical Therapeutics]

Objectives. The aim of this study was to assess the safety of early oral switch (EOS) prior to 14 days for low-risk Staphylococcus aureus bacteremia (LR-SAB), which is the primary treatment strategy employed at our institution. Usually recommended therapy is 14 days of intravenous (IV) antibiotics.

Methods. All patients with SAB at our hospital were identified between 1 January 2014 and 31 December 2018. Those meeting low-risk criteria (healthcare-associated, no evidence of deep infection or demonstrated involvement of prosthetic material, and no further positive blood cultures after 72-hours) were included in the study. The primary outcome was occurrence of a SAB-related complication within 90 days.

Results. There were 469 SAB episodes during the study period, 100 (21%) of whom met inclusion criteria. EOS was performed in 84 patients. In this group, line infection was the source in 79%, methicillin-susceptible S. aureus caused 95% of SABs and 74% of patients received IV flucloxacillin. The median duration of IV and oral antibiotics in the EOS group was 5 (IQR 4-6) and 10 days (IQR 9-14), respectively. Seventy-one percent of patients received flucloxacillin as their EOS agent. Overall, 86% of oral step-down therapy was with beta-lactams. One patient (1%) undergoing EOS had SAB relapse within 90 days. No deaths attributable to SAB occurred within 90 days.

Conclusions. In this low MRSA prevalence LR-SAB cohort, EOS was associated with a low incidence of SAB-related complications. This was achieved with oral beta-lactam therapy in most patients. Larger prospective studies are needed to confirm these findings.




y

Assessment of drug resistance during phase 2b clinical trials of presatovir in adults naturally infected with respiratory syncytial virus [Antiviral Agents]

Background: This study summarizes drug resistance analyses in 4 recent phase 2b trials of the respiratory syncytial virus (RSV) fusion inhibitor presatovir in naturally infected adults.

Methods: Adult hematopoietic cell transplant (HCT) recipients, lung transplant recipients, or hospitalized patients with naturally acquired, laboratory-confirmed RSV infection were enrolled in 4 randomized, double-blind, placebo-controlled studies with study-specific presatovir dosing. Full-length RSV F sequences amplified from nasal swabs obtained at baseline and postbaseline were analyzed by population sequencing. Substitutions at RSV fusion inhibitor resistance-associated positions are reported.

Results: Genotypic analyses were performed on 233 presatovir-treated and 149 placebo-treated subjects. RSV F variant V127A was present in 8 subjects at baseline. Population sequencing detected treatment-emergent substitutions in 10/89 (11.2%) HCT recipients with upper and 6/29 (20.7%) with lower respiratory tract infection, 1/35 (2.9%) lung transplant recipients, and 1/80 (1.3%) hospitalized patients treated with presatovir; placebo-treated subjects had no emergent resistance-associated substitutions. Subjects with substitutions at resistance-associated positions had smaller decreases in viral load during treatment relative to those without, but similar clinical outcomes.

Conclusions: Subject population type and dosing regimen may have influenced RSV resistance development during presatovir treatment. Subjects with vs without genotypic resistance development had decreased virologic responses but comparable clinical outcomes.




y

A histone methyltransferase inhibitor can reverse epigenetically acquired drug resistance in the malaria parasite Plasmodium falciparum [Mechanisms of Resistance]

Malaria parasites invade and replicate within red blood cells (RBCs), extensively modifying their structure and gaining access to the extracellular environment by placing the plasmodial surface anion channel (PSAC) into the RBC membrane. Expression of members of the cytoadherence linked antigen gene 3 (clag3) family is required for PSAC activity, a process that is regulated epigenetically. PSAC is a well-established route of uptake for large, hydrophilic antimalarial compounds and parasites can acquire resistance by silencing clag3 gene expression, thereby reducing drug uptake. We found that exposure to sub-IC50 concentrations of the histone methyltransferase inhibitor chaetocin caused substantial changes in both clag3 gene expression and RBC permeability, reversing acquired resistance to the antimalarial compound blasticidin S that is transported through PSAC. Chaetocin treatment also altered progression of parasites through their replicative cycle, presumably by changing their ability to modify chromatin appropriately to enable DNA replication. These results indicate that targeting histone modifiers could represent a novel tool for reversing epigenetically acquired drug resistance in P. falciparum.




y

An engineered double lipid II binding motifs-containing lantibiotic displays potent and selective antimicrobial activity against E. faecium [Chemistry; Biosynthesis]

Lipid II is an essential precursor of the bacterial cell wall biosynthesis and thereby an important target for various antibiotics. Several lanthionine-containing peptide antibiotics target lipid II with lanthionine-stabilized lipid II-binding motifs. Here, we used the biosynthesis system of the lantibiotic nisin to synthesize a two lipid II binding motifs-containing lantibiotic, termed TL19, which contains the N-terminal lipid II binding motif of nisin and the distinct C-terminal lipid II binding motif of one peptide of the two-component haloduracin (i.e. HalA1). Further characterization demonstrated that (i) TL19 exerts 64-fold stronger antimicrobial activity against E. faecium than nisin (1-22), which has only one lipid II binding site, and (ii) both the N- and C-terminal domains are essential for the potent antimicrobial activity of TL19, as evidenced by mutagenesis of each single and double domains. These results show the feasibility of a new approach to synthesize potent lantibiotics with two different lipid II binding motifs to treat specific antibiotic-resistant pathogens.




y

MK-571, a cysteinyl leukotriene receptor-1 antagonist, inhibits hepatitis C virus (HCV) replication [Antiviral Agents]

The quinoline MK-571 is the most commonly used inhibitor of multidrug resistance protein-1 (MRP-1) but was originally developed as a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. While studying the modulatory effect of MRP-1 on anti-hepatitis C virus (HCV) direct acting-antivirals (DAA) efficiency, we observed an unexpected anti-HCV effect of compound MK-571 alone. This anti-HCV activity was characterized in Huh7.5 cells stably harboring a subgenomic genotype 1b replicon. A dose-dependent decrease of HCV RNA levels was observed upon MK-571 administration, with an EC50 of 9±0.3 μM and a maximum HCV RNA level reduction of approximatively 1 Log10. MK-571 also reduced the replication of the HCV full-length J6/JFH1 model in a dose-dependent manner. However, probenecid and apigenin homodimer (APN), two specific inhibitors of MRP-1, had no effect on HCV replication. In contrast, the CysLTR1 antagonists SR2640 increased HCV-SGR RNA levels in a dose-dependent manner, with a maximum increase of 10-fold. In addition, a combination of natural CysLTR1 agonist (LTD4) or antagonists (zafirlukast, cinalukast, and SR2640) with MK-571 completely reversed its antiviral effect, suggesting its anti-HCV activity is related to CysLTR1 rather to MRP-1 inhibition. In conclusion, we showed that MK-571 inhibits HCV replication in hepatoma cell cultures by acting as a CysLTR1 receptor antagonist, thus unraveling a new host-virus interaction in the HCV life cycle.




y

Significant efficacy of single low dose primaquine compared to stand alone artemisinin combination therapy in reducing gametocyte carriage in Cambodian patients with uncomplicated multidrug resistant Plasmodium falciparum malaria [Epidemiology and Surveil

Since 2012, single low dose of primaquine (SLDPQ, 0.25mg/kg) has been recommended with artemisinin-based combination therapies, as first-line treatment of acute uncomplicated Plasmodium falciparum malaria, to interrupt its transmission, especially in low transmission settings of multidrug, including artemisinin, resistance. Policy makers in Cambodia have been reluctant to implement this recommendation due to primaquine safety concerns and lack of data on its efficacy.

In this randomized controlled trial, 109 Cambodians with acute uncomplicated P. falciparum malaria received dihydroartemisinin-piperaquine (DP) alone or combined with SLDPQ on the first treatment day. Transmission-blocking efficacy of SLDPQ was evaluated on Days 0, 1, 2, 3, 7, 14, 21, 28 and recrudescence by reverse transcriptase polymerase chain reaction (RT-PCR) (gametocyte prevalence) and membrane-feeding assays with Anopheles minimus mosquitoes (gametocyte infectivity). Without the influence of recrudescent infections, DP+SLDPQ reduced gametocyte carriage 3 fold compared to DP. Of 48 patients tested on Day 0, only three patients were infectious to mosquitoes (~6%). Post-treatment, three patients were infectious: on D14 (3.5%, 1/29), and on the first and seventh day of recrudescence (8.3%, 1/12 for each); this overall low infectivity precluded our ability to assess its transmission blocking efficacy.

Our study confirms effective gametocyte clearance of SLDPQ when combined with DP in multidrug resistant P. falciparum and the negative impact of recrudescent infections due to poor DP efficacy. Artesunate-mefloquine (ASMQ) has replaced DP and ASMQ-SLDPQ has been deployed to treat all P. falciparum symptomatic patients to further support the elimination of multidrug resistant P. falciparum in Cambodia.




y

Evaluation of the efficacy of antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in automated time-lapse microscopy and static time-kill experiments [Clinical Therapeutics]

Objectives: Antibiotic combination therapy is used for severe infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Yet, data of which combinations are most effective is lacking. This study aimed to evaluate the in vitro efficacy of polymyxin B in combination with 13 other antibiotics against four clinical strains of MDR Pseudomonas aeruginosa.

Methods: We evaluated the interactions of polymyxin B in combination with amikacin, aztreonam, cefepime, chloramphenicol, ciprofloxacin, fosfomycin, meropenem, minocycline, rifampicin, temocillin, thiamphenicol or trimethoprim by automated time-lapse microscopy using predefined cut-off values indicating inhibition of growth (≤106 CFU/mL) at 24 h. Promising combinations were subsequently evaluated in static time-kill experiments.

Results: All strains were intermediate or resistant to polymyxin B, anti-pseudomonal β-lactams, ciprofloxacin and amikacin. Genes encoding β-lactamases (e.g., blaPAO and blaOXA-50) and mutations associated with permeability and efflux were detected in all strains. In the time-lapse microscopy experiments, positive interactions were found with 39 of 52 antibiotic combination/bacterial strain setups. Enhanced activity was found against all four strains with polymyxin B used in combination with aztreonam, cefepime, fosfomycin, minocycline, thiamphenicol and trimethoprim. Time kill experiments showed additive or synergistic activity with 27 of the 39 tested polymyxin B combinations, most frequently with aztreonam, cefepime, and meropenem.

Conclusion: Positive interactions were frequently found with the tested combinations, also against strains that harboured several resistance mechanisms to the single drugs and with antibiotics that are normally not active against P. aeruginosa. Further study is needed to explore the clinical utility of these combinations.




y

Comparison of Cefepime/Cefpirome and Carbapenem Therapy for Acinetobacter Bloodstream Infection: A Multicentre Study [Clinical Therapeutics]

Carbapenems are currently the preferred agents for the treatment of serious Acinetobacter infections. However, whether cefepime/cefpirome can be used to treat Acinetobacter bloodstream infection (BSI) if it is active against the causative pathogens is not clear. This study aimed to compare the efficacy of cefepime/cefpirome and carbapenem monotherapy in patients with Acinetobacter BSI. The population included 360 patients with monomicrobial Acinetobacter BSI receiving appropriate antimicrobial therapy admitted to four medical centres in Taiwan in 2012–2017. The predictors of 30-day mortality were determined by Cox regression analysis. The overall 30-day mortality rate in the appropriate antibiotic treatment group was 25.0% (90/360 patients), respectively. The crude 30-day mortality rates for cefepime/cefpirome and carbapenem therapy were 11.5% (7/61 patients) and 26.3% (21/80 patients), respectively. The patients receiving cefepime/cefpirome/carbapenem therapy were infected by Acinetobacter nosocomialis (51.8%), A. baumannii (18.4%) and A. pittii (12.1%). After adjusting for age, Sequential Organ Failure Assessment (SOFA) score, invasive procedures, and underlying diseases, cefepime/cefpirome therapy was not independently associated with a higher or lower 30-day mortality compared to the carbapenem therapy. SOFA score (hazard ratio [HR], 1.324; 95% confidence interval [CI], 1.137–1.543; P < 0.001) and neutropenia (HR, 7.060; 95% CI, 1.607–31.019; P = 0.010) were independent risk factors for 30-day mortality of patients receiving cefepime/cefpirome or carbapenem monotherapy. The incidence density of 30-day mortality for cefepime/cefpirome versus carbapenem therapy was 0.40% versus 1.04%. The therapeutic response of cefepime/cefpirome therapy was comparable to that of carbapenems among patients with Acinetobacter BSI receiving appropriate antimicrobial therapy.




y

ZN148 - a modular synthetic metallo-{beta}-lactamase inhibitor reverses carbapenem-resistance in Gram-negative pathogens in vivo [Experimental Therapeutics]

Carbapenem-resistant Gram-negative pathogens are a critical public health threat and there is an urgent need for new treatments. Carbapenemases (β-lactamases able to inactivate carbapenems) have been identified in both serine β-lactamase (SBL) and metallo β-lactamase (MBL) families. The recent introduction of SBL carbapenemase-inhibitors has provided alternative therapeutic options. Unfortunately, there are no approved inhibitors of MBL-mediated carbapenem-resistance and treatment options for infections caused by MBL-producing Gram-negatives are limited. Here, we present ZN148, a zinc-chelating MBL-inhibitor capable of restoring the bactericidal effect of meropenem and in vitro clinical susceptibility to carbapenems in >98% of a large international collection of MBL-producing clinical Enterobacterales strains (n=234). Moreover, ZN148 was able to potentiate the effect of meropenem against NDM-1-producing Klebsiella pneumoniae in a murine neutropenic peritonitis model. ZN148 showed no inhibition of the human zinc-containing enzyme glyoxylase II at 500 μM and no acute toxicity was observed in an in vivo mouse model with cumulative dosages up to 128 mg/kg. Biochemical analysis showed a time-dependent inhibition of MBLs by ZN148 and removal of zinc ions from the active site. Addition of exogenous zinc after ZN148 exposure only restored MBL activity by ~30%, suggesting an irreversible mechanism of inhibition. Mass-spectrometry and molecular modelling indicated potential oxidation of the active site Cys221 residue. Overall, these results demonstrate the therapeutic potential of a ZN148-carbapenem combination against MBL-producing Gram-negative pathogens and that ZN148 is a highly promising MBL inhibitor, capable of operating in a functional space not presently filled by any clinically approved compound.